Adverse drug event reporting systems: a systematic review

被引:57
|
作者
Bailey, Chantelle [1 ,2 ]
Peddie, David [1 ,3 ]
Wickham, Maeve E. [1 ,2 ]
Badke, Katherin [1 ,2 ]
Small, Serena S. [1 ,3 ]
Doyle-Waters, Mary M. [1 ]
Balka, Ellen [1 ,3 ]
Hohl, Corinne M. [1 ,2 ]
机构
[1] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Vancouver Gen Hosp, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada
[3] Simon Fraser Univ, Sch Commun, Burnaby, BC V5A 1A6, Canada
关键词
adverse drug events; data elements; medicines; pharmacovigilance; reporting systems; systematic review; QUALITY; DOCUMENTATION; PRESCRIPTION; INFORMATION; DATABASES; FORMS;
D O I
10.1111/bcp.12944
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIM Adverse drug events (ADEs) are harmful and unintended consequences of medications. Their reporting is essential for drug safety monitoring and research, but it has not been standardized internationally. Our aim was to synthesize information about the type and variety of data collected within ADE reporting systems. METHODS We developed a systematic search strategy, applied it to four electronic databases, and completed an electronic grey literature search. Two authors reviewed titles and abstracts, and all eligible full-texts. We extracted data using a standardized form, and discussed disagreements until reaching consensus. We synthesized data by collapsing data elements, eliminating duplicate fields and identifying relationships between reporting concepts and data fields using visual analysis software. RESULTS We identified 108 ADE reporting systems containing 1782 unique data fields. We mapped them to 33 reporting concepts describing patient information, the ADE, concomitant and suspect drugs, and the reporter. While reporting concepts were fairly consistent, we found variability in data fields and corresponding response options. Few systems clarified the terminology used, and many used multiple drug and disease dictionaries such as the Medical Dictionary for Regulatory Activities (MedDRA). CONCLUSION We found substantial variability in the data fields used to report ADEs, limiting the comparability of ADE data collected using different reporting systems, and undermining efforts to aggregate data across cohorts. The development of a common standardized data set that can be evaluated with regard to data quality, comparability and reporting rates is likely to optimize ADE data and drug safety surveillance.
引用
收藏
页码:17 / 29
页数:13
相关论文
共 50 条
  • [21] An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions
    Vinther, Siri
    Klarskov, Pia
    Borgeskov, Hanne
    Darso, Perle
    Christophersen, Anette Kvindebjerg
    Borck, Bille
    Christensen, Catrine
    Hansen, Melissa Voigt
    Halladin, Natalie Monica Lovland
    Christensen, Mikkel Bring
    Harboe, Kirstine Moll
    Lund, Marie
    Jimenez-Solem, Espen
    [J]. DANISH MEDICAL JOURNAL, 2017, 64 (01):
  • [22] A systematic review to evaluate the accuracy of electronic adverse drug event detection
    Forster, Alan J.
    Jennings, Alison
    Chow, Claire
    Leeder, Ciera
    van Walraven, Carl
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2012, 19 (01) : 31 - 38
  • [23] About adverse event reporting and recording systems
    Aranaz Andres, Jesus Maria
    [J]. REVISTA DE CALIDAD ASISTENCIAL, 2009, 24 (01) : 1 - 2
  • [24] Adverse Event Reporting Priorities: An Integrative Review
    Falcone, Maureen L.
    Van Stee, Stephanie K.
    Tokac, Umit
    Fish, Anne F.
    [J]. JOURNAL OF PATIENT SAFETY, 2022, 18 (04) : E727 - E740
  • [25] Adverse event reporting systems and safer healthcare
    Battles, James B.
    Stevens, David P.
    [J]. QUALITY & SAFETY IN HEALTH CARE, 2009, 18 (01): : 2 - 2
  • [26] Toward improved adverse event/suspected adverse drug reaction reporting
    Gross, R
    Strom, BL
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (02) : 89 - 91
  • [27] Adverse drug event reporting at veterans affairs facilities
    Corr, K
    Stoller, R
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (03) : 314 - 315
  • [28] Poor quality of adverse event reporting in oncology phase III trials: A systematic review
    Maillet, D.
    You, B.
    Peron, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S193 - S194
  • [29] Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review
    Hunsinger, Matthew
    Smith, Shannon M.
    Rothstein, Daniel
    McKeown, Andrew
    Parkhurst, Melissa
    Hertz, Sharon
    Katz, Nathaniel P.
    Lin, Allison H.
    McDermott, Michael P.
    Rappaport, Bob A.
    Turk, Dennis C.
    Dworkin, Robert H.
    [J]. PAIN, 2014, 155 (11) : 2253 - 2262
  • [30] AI as a Medical Device Adverse Event Reporting in Regulatory Databases: Protocol for a Systematic Review
    Kale, Aditya U.
    Dattani, Riya
    Tabansi, Ashley
    Hogg, Henry David Jeffry
    Pearson, Russell
    Glocker, Ben
    Golder, Su
    Waring, Justin
    Liu, Xiaoxuan
    Moore, David J.
    Denniston, Alastair K.
    [J]. JMIR RESEARCH PROTOCOLS, 2024, 13